头孢他啶阿维巴坦联合氨曲南治疗产金属β-内酰胺酶肠杆菌科细菌感染的临床应用进展

Advances in the clinical application of ceftazidime-avibactam combined with aztreonam in the treatment of metallo-β-lactamase-producing Enterobacteriaceae infections

随着细菌耐药问题的日益突出,产金属β-内酰胺酶肠杆菌科细菌感染成为临床的棘手问题。近年来头孢他啶阿维巴坦(ceftazidime-avibactam, CAZ-AVI)联合氨曲南(aztreonam, ATM)治疗产金属β-内酰胺酶肠杆菌科细菌感染显示出良好的临床疗效。此文纳入了1篇前瞻性观察性研究,1篇回顾性研究,8篇病例报道,共计患者121例,其中前瞻性观察性研究102例,回顾性研究10例,病例报道9例。前瞻性观察性研究显示:头孢他啶阿维巴坦+氨曲南(ceftazidime-avibactam+aztreonam, CZA-AZT)的临床疗效显著优于其他抗感染方案;回顾性研究显示:10例患者中有9例被CZA-AZT成功治愈;病例报道显示:9例患者均被CZA-AZT成功治愈。CZA-AZT有望成为临床治疗产金属β-内酰胺酶肠杆菌科细菌感染性疾病的新选择。

With the increasingly prominent problem of bacterial resistance, the infection induced by metallo-β-lactamase-producing enterobacteriaceae has become a difficult clinical problem. In recent years, ceftazidime-avibactam combined with aztreonam has shown good clinical efficacy in the treatment of metallo-β-lactamase-producing enterobacteriaceae bacterial infections. This article included one prospective observational study, one retrospective study and 8 case reports with a total of 121 patients including 102 in the prospective observational studies, 10 in the retrospective studies and 9 in the case reports. The prospective observational studies have shown that the clinical efficacy of ceftazidime-avibactam+aztreonam(CZA-AZT) was significantly better than that of other anti-infective regimens;the retrospective studies have shown 9 out of 10 patients were successfully cured by CZA-AZT;the case reports have showed that all the 9 patients were successfully cured by CZA-AZT. CZA-AZT is expected to become a new choice for the clinical treatment of infectious diseases caused by metal β-lactamase-producing Enterobacteriaceae.